Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Sidec and Genmab use protein tomography to study cancer cell growth

Sidec : 24 April, 2008  (Company News)
Sidec in partnership with Genmab has determined the molecular mode of action of HuMax-EGFr (zalutumumab).
The investigation showed that zalutumumab locks the epidermal growth factor receptor (EGFr) molecules into a compact, inactive conformation. Flexibility is crucial to the role of the EGFr in signalling, and this study, done with Sidec's proprietary methodology Protein Tomography, has played a central role in the understanding of the inhibition of individual EGFr molecules.

Moreover, Sidec's technology confirmed that HuMax-EGFr binds bivalently to the EGFr. Prevention of the receptor dimerization as well as locking the EGFr molecules in the inactive form both contribute to the inhibition of signalling and cancer cell growth.

The data will be demonstrated on Sidec's First Protein Tomography Symposium at the fourth annual PEGS Summit April 28 to May 2, 2008 at the Intercontinental Hotel in Boston, Massachusetts, USA.

With Protein Tomography it is possible to study the molecular mode of action of individual molecules in situ and in vitro. The biological information obtained can also be used to prioritise the most promising monoclonal antibodies/projects and to locate the antibody binding epitope.

'These results clearly show the importance of understanding the molecular mode of action and to capture the flexibility of a receptor when developing therapeutic antibodies. Today this can only be done with Protein Tomography and we are proud to have contributed to Genmab's new insight to HuMax-EGFr mechanism of action.' said Hans Johansson chief executive officer at Sidec.

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo